
Immuneering Corp (IMRX) Stock Forecast & Price Target
Immuneering Corp (IMRX) Analyst Ratings
Bulls say
Immuneering is viewed positively because atebimetinib appears to solve a long-standing MEK-class problem: it delivers deep MAPK suppression through Deep Cyclic Inhibition while avoiding the chronic toxicity and adaptive pathway reactivation that limited earlier inhibitors. In first-line PDAC, the 55-patient cohort produced a 17.3-month median OS, 8.3-month median PFS, 36% ORR, and 82% DCR, with tolerability remaining clean enough that only anemia and neutropenia exceeded Grade 3 in more than 10% of patients and 84% of patients maintained or gained weight. That combination of differentiated biology, durable survival signal, and validation-ready Phase 3 design in approximately 510 patients, supported by about $199 million of cash and runway into 2029, underpins the bullish outlook.
Bears say
Immuneering is viewed negatively because atebimetinib’s value proposition in PDAC looks fragile: direct RAS inhibitors may move into first-line treatment first, leaving a more crowded and less differentiated market where a chemotherapy-combination must compete against more targeted, potentially better-tolerated options. The company’s clinical case also rests heavily on a small single-arm Phase 2 signal, while the Phase 3 MAPKeeper study faces risks from OS dilution, greater patient heterogeneity across 510 patients globally, and the possibility that better post-progression therapy blunts the endpoint. Fundamentally, Immuneering also has the typical biotech burden of operating losses, potential future capital raises, regulatory and manufacturing risk, and no approved products or commercial infrastructure to offset execution risk.
This aggregate rating is based on analysts' research of Immuneering Corp and is not a guaranteed prediction by Public.com or investment advice.
Immuneering Corp (IMRX) Analyst Forecast & Price Prediction
Start investing in Immuneering Corp (IMRX)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Immuneering Corp (IMRX) Forecast
Immuneering Corp (IMRX) Analyst Forecast & Price Prediction
Start investing in Immuneering Corp (IMRX)
Order type
Buy in
Order amount
Est. shares
0 shares